Acrivon Therapeutics, Inc. Common Stock (ACRV)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	43.61 mm	43.61 mm	43.61 mm	43.61 mm	43.61 mm	43.61 mm
Cash burn (monthly)	938.67 k	(no burn)	8.38 mm	7.11 mm	5.77 mm	5.06 mm
Cash used (since last report)	4.01 mm	n/a	35.79 mm	30.35 mm	24.66 mm	21.59 mm
Cash remaining	39.60 mm	n/a	7.83 mm	13.26 mm	18.95 mm	22.02 mm
Runway (months of cash)	42.2	n/a	0.9	1.9	3.3	4.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

ACRV institutional ownership history Ownership history

93.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	57	57	–
Opened positions	8	12	-33.3%
Closed positions	8	5	+60.0%
Increased positions	17	24	-29.2%
Reduced positions	14	6	+133.3%

13F shares	Current	Prev Q	Change
Total value	160.53 bn	135.93 bn	+18.1%
Total shares	29.06 mm	29.55 mm	-1.7%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Ra Capital Management	8.34 mm	$58.38 bn	0.0%
Perceptive Advisors	5.36 mm	$37.53 bn	0.0%
Chione	3.85 mm	$22.55 mm	0.0%
Citadel Advisors	2.14 mm	$14.98 bn	+1.0%
Sands Capital Ventures	2.12 mm	$14.86 bn	0.0%
Sands Capital Life Sciences Pulse Fund II	1.65 mm	$27.50 mm	0.0%
Wellington Management	888.13 k	$6.22 bn	0.0%
Marshall Wace	809.86 k	$5.67 bn	-14.6%
BlackRock	786.98 k	$5.51 bn	NEW
Vanguard	637.54 k	$4.46 bn	-14.5%

Largest transactions	Shares	Bought/sold	Change
BlackRock	786.98 k	+786.98 k	NEW
BLK BlackRock	0.00	-767.02 k	EXIT
Paradigm Biocapital Advisors	0.00	-659.72 k	EXIT
GS The Goldman Sachs Group, Inc.	198.17 k	+173.78 k	+712.7%
Marshall Wace	809.86 k	-139.01 k	-14.6%
Exome Asset Management	116.76 k	+116.76 k	NEW
Vanguard	637.54 k	-107.97 k	-14.5%
STT State Street	225.90 k	+47.23 k	+26.4%
Millennium Management	39.75 k	+39.75 k	NEW
Prelude Capital Management	37.73 k	+37.73 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ACRV insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
17 Jan 25	Mary Miller	Common Stock	Payment of exercise	Dispose F	No	No	5.78	659	3.81 k	37,282
21 Nov 24	Peter Blume-Jensen	Common Stock	Payment of exercise	Dispose F	No	No	6.44	19,910	128.22 k	2,342,837
14 Nov 24	Peter Blume-Jensen	Common Stock	Payment of exercise	Dispose F	Yes	No	7.92	490	3.88 k	316,756
14 Nov 24	Peter Blume-Jensen	Common Stock	Payment of exercise	Dispose F	No	No	7.92	59,766	473.35 k	2,362,747
14 Nov 24	Eric Devroe	Common Stock	Payment of exercise	Dispose F	No	No	7.92	613	4.85 k	67,871
14 Nov 24	Erick Gamelin	Common Stock	Payment of exercise	Dispose F	No	No	7.92	402	3.18 k	16,961

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Cantor Fitzgerald Initiates Coverage On Acrivon Therapeutics with Overweight Rating

31 Jan 25

Cantor Fitzgerald analyst Li Watsek initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with a Overweight rating.

BMO Capital Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $27

14 Nov 24

BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics (NASDAQ:ACRV) with a Outperform and lowers the price target from $28 to $27.

HC Wainwright & Co. Reiterates Buy on Acrivon Therapeutics, Maintains $22 Price Target

14 Nov 24

HC Wainwright & Co. analyst Emily Bodnar reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Buy and maintains $22 price target.

Acrivon Therapeutics Q3 2024 GAAP EPS $(0.59) Misses $(0.57) Estimate, Cash, Cash Equivalents And Marketable Securities Of $202.8M Expected To Fund Operations Into The Second Half Of 2026

13 Nov 24

Press releases

From Benzinga Pro

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

13 Nov 24

– Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient selection (p = 0.009) from ongoing ACR-368 registrational-intent Phase 2b